Claims
- 1. A method for treating a disease, comprising administering to human or animal in need of such treatment an effective amount of a monoclonal antibody which specifically binds to fibroblast growth factor-8 (FGF-8) and inhibits activity of FGF-8.
- 2. The method according to claim 1, wherein the monoclonal antibody is a monoclonal antibody which specifically binds to SEQ ID NO:1.
- 3. The method according to claim 1, wherein the monoclonal antibody is a humanized antibody or the antibody fragment thereof.
- 4. The method according to claim 3, which comprises complementarity determining region (CDR) 1, CDR2 and CDR3 of an antibody heavy chain (H chain) variable region (V region) comprising the amino acid sequences represented by SEQ ID NOs:7, 8 and 9, respectively.
- 5. The method according to claim 3, which comprises complementarity determining region (CDR) 1, CDR2 and CDR3 of an antibody light chain (L chain) variable region (V region) comprising the amino acid sequences represented by SEQ ID NOs:10, 11 and 12, respectively.
- 6. The method according to claim 3, which comprises CDR1, CDR2 and CDR3 of an antibody heavy chain (H chain) variable region (V region) comprising the amino acid sequences represented by SEQ ID NOs:7, 8 and 9, respectively, and CDR1, CDR2 and CDR3 of an antibody light chain (L chain) variable region (V region) comprising the amino acid sequences represented by SEQ ID NOs:10, 11 and 12, respectively.
- 7. The method according to claim 3, wherein the humanized antibody is a human chimeric antibody or a human CDR-grafted antibody.
- 8. The method according to claim 7, wherein the human chimeric antibody comprises a heavy chain (H chain) variable region (V region) and a light chain (L chain) V region of a monoclonal antibody against FGF-8.
- 9. The method according to claim 7, wherein the human chimeric antibody comprises a heavy chain (H chain) variable region (V region) and a light chain (L chain) V region of a monoclonal antibody against FGF-8, and an H chain constant region (C region) and an L chain C region of a human antibody.
- 10. The method according to claim 7, wherein VL of the antibody comprises an amino acid sequence represented by SEQ ID NO:42.
- 11. The method according to claim 7, wherein VH of the antibody comprises an amino acid sequence represented by SEQ ID NO:43.
- 12. The method according to claim 7, wherein VH and VL of the antibody comprise amino acid sequences represented by SEQ ID NOs:42 and 43, respectively.
- 13. The method according to claim 7, wherein VH and VL of the antibody comprise amino acid sequences represented by SEQ ID NOs:42 and 43, respectively.
- 14. The method according to claim 7, wherein the human CDR-grafted antibody comprises CDRs of VH and VL of a monoclonal antibody against FGF-8.
- 15. The method according to claim 7, wherein the human CDR-grafted antibody comprises CDRs of VH and VL of a monoclonal antibody against FGF-8, and framework regions (FRs) of VH and VL of a human antibody.
- 16. The method according to claim 7, wherein the human CDR-grafted antibody comprises CDs of VH and VL of a monoclonal antibody against FGF-8, and an H chain C region and an L chain C region of a human antibody.
- 17. The method according to claim 7, wherein CDR1, CDR2 and CDR3 of VH of the antibody comprise amino acid sequences represented by SEQ ID NOs:7, 8 and 9, respectively.
- 18. The method according to claim 7, wherein CDR1, CDR2 and CDR3 of VL of the antibody comprise amino acid sequences represented by SEQ ID NOs:10, 11 and 12, respectively.
- 19. The method according to claim 7, wherein CDR1, CDR2 and CDR3 of VH of the antibody comprises amino acid sequences represented by SEQ ID NOs:7, 8 and 9, respectively, and wherein CDR1, CDR2 and CDR3 of VL of the antibody comprises amino acid sequences represented by SEQ ID NOs:10, 11 and 12, respectively.
- 20. The method according to claim 7, wherein VH of the antibody comprises an amino acid sequence in which at least one amino acid residue selected from Lys at position 12, Lys at position 13, Ala at position 40, Pro at position 41, Met at position 48, Val at position 68, Ile at position 70, Thr at position 74, Thr at position 76, Glu at position 82, Ser at position 84, Arg at position 87 and Tyr at position 95 in the amino acid sequence represented by SEQ ID NO: 18 is substituted.
- 21. The method according to claim 7, wherein VL of the antibody comprises an amino acid sequence in which at least one amino acid residue selected from Ile at position 12, Val at position 3, Thr at position 14, Pro at position 15, Gln at position 50, Leu at position 51 and Tyr at position 92 in the amino acid sequence represented by SEQ ID NO:19 is substituted.
- 22. The method according to claim 7, wherein VH of the antibody comprises an amino acid sequence in which at least one amino acid residue selected from Lys at position 12, Lys at position 13, Ala at position 40, Pro at position 41, Met at position 48, Val at position 68, Ile at position 70, Thr at position 74, Thr at position 76, Glu at position 82, Ser at position 84, Arg at position 87 and Tyr at position 95 in the amino acid sequence represented by SEQ ID NO; 18 is substituted, and wherein VL of the antibody comprises an amino acid sequence in which at least one amino acid residue selected from Ile at position 2, Val at position 3, Thr at position 14, Pro at position 15, Gin at position 50, Leu at position 51 and Tyr at position 92 in the amino acid sequence represented by SEQ ID NO:19 is substituted.
- 23. The method according to claim 7, wherein VH of the antibody comprises the amino acid sequence represented by SEQ ID NO:18 or 20.
- 24. The method according to claim 7, wherein VL of the antibody comprises the amino acid sequence represented by SEQ ID NO:19, 21, 40 or 41.
- 25. The method according to claim 7, wherein VH of the antibody comprises the amino acid sequence represented by SEQ ID NO:18 or 20, and wherein VL of the antibody comprises the amino acid sequence represented by SEQ ID NO; 19, 21, 40 or 41.
- 26. The method according to claim 7, wherein VH and VL of the antibody comprise amino acid sequences represented by SEQ ID NOs:18 and 21, respectively.
- 27. The method according to claim 7, wherein VH and VL of the antibody comprise amino acid sequences represented by SEQ ID NOs:18 and 40, respectively.
- 28. The method according to claim 7, wherein VH and VL of the antibody comprise amino acid sequences represented by SEQ ED NOs:18 and 41, respectively.
- 29. The method according to claim 3, wherein the antibody fragment is selected from the group consisting of Fab, Fab′, F(ab′)2, a single chain antibody (scFv), a dimerized variable region (V region) fragment (diabody), a disulfide-stabilized V region fragment (dsFv) and a peptide comprising a complementarity determining region (CDR).
- 30. The method according to claim 1, wherein the monoclonal antibody is a monoclonal antibody belonging to the IgG1 subclass produced by hybridoma FERM BP-5451.
- 31. The method according to claim 1, wherein the monoclonal antibody is a humanized antibody produced by a transformant FERM BP-7836, FERM BP-8082, FERM BP-8083 or FERM BP-8084.
- 32. The method according to claim 1, wherein the diseases are cancer diseases.
- 33. The method according to claim 32, wherein the cancer disease is prostate cancer, breast cancer or ovarian cancer.
Priority Claims (1)
Number |
Date |
Country |
Kind |
P. HEI. 8-81754 |
Apr 1996 |
JP |
|
Parent Case Info
[0001] This application is a continuation-in-part of Ser. No. 09/876,040 filed Jun. 8, 2001, which is a division of Ser. No. 09/326,590 filed Jun. 7, 1999, now U.S. Pat. No. 6,310,184, which is a division of Ser. No. 08/832,236 filed Apr. 3, 1997, now U.S. Pat. No. 5,952,472.
Divisions (2)
|
Number |
Date |
Country |
Parent |
09326590 |
Jun 1999 |
US |
Child |
09876040 |
Jun 2001 |
US |
Parent |
08832236 |
Apr 1997 |
US |
Child |
09326590 |
Jun 1999 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09876040 |
Jun 2001 |
US |
Child |
10434469 |
May 2003 |
US |